Education
About Us
Working with TipRanks
Follow Us
MacroGenics Inc (MGNX)
:MGNX
MGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $5.10
Previous CloseN/A
Volume157.79K
Average Volume (3M)1.03M
Market Cap
$106.62M
Enterprise Value-$36.71M
Total Cash (Recent Filing)$154.14M
Total Debt (Recent Filing)$37.47M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Aug 12, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding63,090,324
10 Day Avg. Volume836,604
30 Day Avg. Volume1,034,788
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.34
Enterprise Value/Revenue-0.24
Enterprise Value/Gross Profit-0.27
Enterprise Value/Ebitda0.78
Forecast
1Y Price Target
$4.75Price Target Upside189.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Pipeline ProgressMGNX continues to make progress across its broader pipeline, including the initiation of the Phase II LINNET study and the upcoming clinical update from the Phase II LORIKEET study.
Resource AllocationThe discontinuation of vobra duo is viewed positively as it allows the company to reallocate resources to programs with higher probability of success, including the second B7-H3 ADC program, MGC026.
Bears Say
Development RisksRisks include clinical setbacks with MGC026, lorigerlimab, MGC028, and MGC030, competitive landscape risks, partnership risks, and possible long-term dilution risk.
Financial PerformanceMacroGenics reported a full-year 2024 net loss of $1.07 per share, slightly wider than the previous forecast of a net loss of $0.95 per share.
Price Target RevisionThe 12-month price target has been lowered to $2 per share from the prior $4 per share.
MacroGenics News
MGNX FAQ
What was MacroGenics Inc’s price range in the past 12 months?
MacroGenics Inc lowest stock price was $0.99 and its highest was $5.10 in the past 12 months.
What is MacroGenics Inc’s market cap?
MacroGenics Inc’s market cap is $106.62M.
When is MacroGenics Inc’s upcoming earnings report date?
MacroGenics Inc’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.
How were MacroGenics Inc’s earnings last quarter?
MacroGenics Inc released its earnings results on May 13, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.726 by $0.076.
Is MacroGenics Inc overvalued?
According to Wall Street analysts MacroGenics Inc’s price is currently Undervalued.
Does MacroGenics Inc pay dividends?
MacroGenics Inc does not currently pay dividends.
What is MacroGenics Inc’s EPS estimate?
MacroGenics Inc’s EPS estimate is -0.42.
How many shares outstanding does MacroGenics Inc have?
MacroGenics Inc has 63,090,324 shares outstanding.
What happened to MacroGenics Inc’s price movement after its last earnings report?
MacroGenics Inc reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.726. Following the earnings report the stock price went up 0.649%.
Which hedge fund is a major shareholder of MacroGenics Inc?
Currently, no hedge funds are holding shares in MGNX
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.75 (189.63% Upside)
$4.75 (189.63% Upside)
Blogger Sentiment
Neutral
MGNX Sentiment 50%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.76%
12-Months-Change
Fundamentals
Return on Equity
-60.25%
Trailing 12-Months
Asset Growth
-9.55%
Trailing 12-Months
Company Description
MacroGenics Inc
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company operates primarily in the biotechnology and pharmaceutical sectors, leveraging its proprietary DART and TRIDENT platforms to create multi-specific antibodies that engage the immune system to eradicate cancer cells. MacroGenics' pipeline includes several product candidates in various stages of clinical trials, targeting a range of cancers, with an emphasis on addressing unmet medical needs.
MGNX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
MacroGenics achieved significant clinical and financial milestones in 2024, marked by a substantial increase in revenues and strong progress in clinical trials. However, increased net losses and operating expenses, along with the discontinuation of vobra duo, present challenges. The company remains financially stable with a solid cash position and is poised for future growth.View all MGNX earnings summariesMGNX Stock 12 Month Forecast
Average Price Target
$4.75
▲(189.63% Upside)
Technical Analysis
Vaxart
―
Pliant Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
11.14% Insiders
17.10% Mutual Funds
42.73% Other Institutional Investors
22.00% Public Companies and
Individual Investors